Phaseline

Companies › Nurix Therapeutics

Nurix Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 6 registered trials: 4 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NX-5948
Non-covalent BTK inhibitor
BTKPhase 3B-cell Lymphoma; Chronic Lymphocytic Leukemia (CLL)Jan 2027
NX-2127
Btk inhibitor
–Phase 1Chronic Lymphocytic Leukemia (CLL)May 2027
NX-1607
Cbl-b inhibitor
CBL-BPhase 1Ovarian Cancer, EpithelialFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05131022NX-5948Phase 1Chronic Lymphocytic Leukemia (CLL)OncologyJan 2027
NCT04830137NX-2127Phase 1Chronic Lymphocytic Leukemia (CLL)OncologyMay 2027
NCT07221500NX-5948Phase 2Chronic Lymphocytic Leukemia (CLL)OncologyJan 2028
NCT05107674NX-1607Phase 1Ovarian Cancer, EpithelialOncologyFeb 2028
NCT07516093NX-5948Phase 3B-cell LymphomaOncologyOct 2029
NCT07520006NX-5948Phase 1B-cell LymphomaOncologyMay 2033

From the company's SEC filings

Cash and short-term investments of $1.1bn on 2026-08-31; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

BTK (1) CBL-B (1)

Companies with the same targets

Sanofi BeOne Medicines Eli Lilly AstraZeneca Guangzhou Lupeng Pharmaceutical Company Zenas BioPharma (USA) Carna Biosciences Merck & Co. (MSD) Acerta Pharma Beijing InnoCare Pharma Tech

Companies built like this

Compass Therapeutics TransThera Sciences (Nanjing) NOBO Medicine Day One Biopharmaceuticals Nuvalent

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.